🔍 Observations
Topline
- Revenue from operations grew 11.2% YoY (₹525,784 Mn → ₹584,620 Mn), driven by both domestic formulations and specialty/global generic expansion.
- Q4FY26 revenue of ₹146,118 Mn grew 12.8% YoY vs Q4FY25 (₹129,588 Mn), though declined 5.9% QoQ from Q3FY26’s ₹155,205 Mn — seasonal softness, not structural.
- Other operating revenues fell sharply (₹5,372 Mn → ₹2,419 Mn YoY), a ₹2,953 Mn headwind to topline largely absorbed by core revenue momentum.
Bottomline
- Reported PAT grew 5.0% YoY (₹109,290 Mn → ₹114,794 Mn); adjusted for ₹13,075 Mn of exceptional items in FY26 vs ₹6,779 Mn in FY25, underlying PAT growth is broadly similar.
- Tax outflow surged — effective tax rate on reported PBT rose from ~17.4% to ~26.0% — compressing PAT despite strong EBIT growth; a large one-off deferred tax reversal benefited FY25.
- EPS grew modestly from ₹45.6 to ₹47.8 (basic), with no dilution — share count flat at ~2,399 Mn shares.
Margins
- EBITDA (PBT before exceptional + Finance costs + D&A): FY26 = ₹151,189 + ₹3,389 + ₹29,379 = ₹183,957 Mn on revenue of ₹584,620 Mn → EBITDA margin ~31.5% vs FY25: ₹137,521 + ₹2,314 + ₹25,754 = ₹165,589 Mn on ₹525,784 Mn → 31.5%. Margins held flat despite R&D intensity rising.
- Net profit margin: ₹114,794 / ₹584,620 = 19.6% vs ₹109,290 / ₹525,784 = 20.8% — 120 bps compression, driven entirely by tax normalisation.
- R&D spend rose to ₹34,741 Mn (5.9% of revenue) vs ₹31,542 Mn (6.0%) — pipeline investment sustained without margin sacrifice.
Growth Trajectory
- Three-year revenue compound implied by 11.2% topline growth and consistent specialty mix shift signals durable mid-teens USD revenue CAGR in global markets.
- Employee costs grew 14.5% YoY (₹99,731 Mn → ₹114,189 Mn), outpacing revenue — talent investment for specialty scaling, but warrants monitoring.
- Other expenses grew 13.3% YoY (₹167,718 Mn → ₹190,083 Mn) — faster than revenue, suggesting operating leverage yet to fully materialise.
🧮 Profit & Loss Statement
🧮 Balance Sheet
🧮 Cash Flows Statement
🟢 Green Flags
- Revenue growth of 11.2% YoY on a large base (₹525 Bn) signals broad-based demand across geographies, not a low-base effect.
- EBITDA margins held flat at ~31.5% despite elevated R&D and employee cost inflation — operational discipline is intact.
- Balance sheet equity grew ₹114 Bn (₹724,860 Mn → ₹838,797 Mn), reflecting strong retained earnings accretion.
- Current investments surged to ₹209,335 Mn from ₹136,561 Mn — excess liquidity being actively deployed in financial assets, not left idle.
- FCF solid: Operating cash flow of ₹124,192 Mn funded ₹36,094 Mn capex and ₹39,339 Mn dividend — self-funded capital allocation with no equity dilution.
- Forex gain of ₹12,402 Mn in FY26 vs ₹1,855 Mn in FY25 — USD-heavy revenue base benefits from rupee depreciation, structurally positive.
- Debt remains negligible — total borrowings (current + non-current) of ~₹40,816 Mn against equity of ₹838,797 Mn; near debt-free.
🔴 Red Flags
- Operating cash flow declined from ₹140,721 Mn to ₹124,192 Mn despite higher PBT — ₹23,139 Mn tax paid vs ₹4,768 Mn in FY25 is the primary cause; one-off but cash is out.
- Trade receivables up ₹24,636 Mn YoY (₹130,461 → ₹155,097 Mn), growing faster than revenue (18.9% vs 11.2%) — collection cycles may be lengthening in global markets.
- Exceptional items of ₹13,075 Mn in FY26 (vs ₹6,779 Mn in FY25) are recurring in nature — repeated “one-offs” reduce quality of earnings signal.
- Acquisition spend of ₹34,051 Mn drove investing outflow to ₹113,441 Mn vs ₹53,062 Mn — goodwill + intangibles now ₹217,082 Mn (25% of total assets); integration risk elevated.
- Other intangible assets jumped from ₹36,109 Mn to ₹118,751 Mn — likely acquisition-related; impairment risk if acquired assets underperform.
- Employee costs outpaced revenue by 330 bps — specialty build-out costs are real, but sustained divergence erodes margin headroom.
- Current borrowings rose from ₹18,671 Mn to ₹40,504 Mn — more than doubled; likely acquisition financing, but needs normalisation.
📊 Balance Sheet Analysis
- Asset quality is adequate but acquisition-heavy: Intangibles + goodwill = ₹217,082 Mn (20% of assets), up sharply from ₹125,503 Mn — fair value and impairment discipline will matter.
- Liquidity is robust: Cash + current investments = ₹307,040 Mn vs current borrowings of ₹40,504 Mn — coverage of 7.6x; no near-term liquidity stress.
- Leverage near-zero on a net basis: Gross debt ~₹40,816 Mn vs cash + liquid investments of ~₹307,040 Mn implies net cash position of ~₹266,224 Mn.
- Working capital stretched: Receivables growth + inventory build (₹102,433 → ₹114,929 Mn) consumed ~₹37,139 Mn of incremental capital in FY26.
💰 Cash Flow Analysis
- Operating CF of ₹124,192 Mn is healthy in absolute terms but optically weaker YoY due to tax normalisation (₹23,139 Mn paid vs ₹4,768 Mn); underlying operating cash generation improved.
- FCF (OCF – capex): ₹124,192 Mn – ₹36,094 Mn = ₹88,098 Mn — strong and comfortably covers the ₹39,339 Mn dividend with ₹48,759 Mn to spare.
- Investing outflow of ₹113,441 Mn reflects ₹34,051 Mn acquisition spend and aggressive net investment in financial assets — capital is being deployed, not hoarded.
- Financing CF of -₹25,126 Mn: Dividend + net borrowing increase broadly offset, balance sheet discipline maintained despite M&A.
💡 Investment Outlook
Sun Pharma delivered steady 11% topline growth with EBITDA margins holding at ~31.5%, confirming the specialty pivot is sustaining revenue quality without margin erosion.
The headline PAT growth of 5% understates underlying earnings power — strip out tax normalisation and exceptional volatility, and the operating trajectory is strong.
The key re-rating catalyst is margin inflection: if specialty-led operating leverage begins flowing through (employee and other expenses growing faster than revenue is the primary watch item), a step-up in EBITDA margins from 31.5% toward 34–35% would validate the premium multiple.
Near-term risk is concentrated in acquisition integration quality — the sharp intangibles jump and receivables build deserve close tracking over the next two quarters.
Disclaimer: This post features ChartAlert-AI-generated financial content which may contain inaccuracies or errors. This commentary is strictly for informational purposes and does not constitute a recommendation to buy or sell any security. Investors are responsible for performing their own due diligence; always consult with a licensed financial advisor before making investment decisions.
Beyond the Price Action: Fundamental Analysis is Coming to ChartAlert
ChartAlert is evolving into integrated research with a future update that will embed fundamental data into your workflow. Alongside technical analysis, the new release will allow access to financial data, quarterly results review, earnings call transcripts, and valuation tools, connecting price action with corporate performance for smarter, data‑driven decisions.